PT-141 (Bremelanotide) vs MOTS-c: Real-World Evidence Comparison

What Are PT-141 and MOTS-c?

PT-141 and MOTS-c are both injectable peptides used in compounding and telehealth settings, but they share almost nothing else. PT-141 (bremelanotide) is a cyclic heptapeptide and FDA-approved drug that acts on central melanocortin receptors to increase sexual desire. MOTS-c is a 16-amino-acid mitochondrial-derived peptide that signals through AMPK to improve glucose metabolism and physical endurance. Comparing them is clinically meaningful only when a patient or prescriber is deciding which of their respective indications to address first, or when evaluating whether a compounded stack is appropriate.

PT-141 (Bremelanotide): Mechanism and Approval History

Bremelanotide was approved by the FDA on June 21, 2019, under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The drug is a synthetic analog of alpha-melanocyte-stimulating hormone. It binds melanocortin receptors MC3R and MC4R in the hypothalamus, activating dopaminergic pathways associated with sexual motivation [2]. Unlike phosphodiesterase-5 inhibitors, PT-141 works centrally rather than peripherally, which is why it can increase desire even in the absence of genital arousal cues.

The approved dose is 1.75 mg delivered as a single subcutaneous injection to the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Patients are instructed to use no more than one dose in 24 hours and no more than one dose per week. The FDA label carries a boxed warning for transient increases in blood pressure and a precaution against use in patients with cardiovascular disease [1].

MOTS-c: Origin and Metabolic Mechanism

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) was first characterized by Lee et al. In a landmark 2015 study published in Cell Metabolism [3]. The peptide is encoded not in nuclear DNA but in mitochondrial DNA, specifically within the 12S ribosomal RNA gene. This makes MOTS-c part of a newly recognized class of mitochondrial-derived peptides (MDPs) that include humanin and SHLP2.

At the cellular level, MOTS-c inhibits the folate cycle and de novo purine synthesis, causing AICAR accumulation and downstream AMPK activation [3]. AMPK activation increases glucose uptake, fatty acid oxidation, and mitochondrial biogenesis, producing effects that resemble moderate aerobic exercise at the tissue level. In the 2015 Lee study, exogenous MOTS-c administration in mice on a high-fat diet prevented obesity and improved insulin sensitivity [3]. Circulating MOTS-c levels in humans decline with age and are lower in individuals with type 2 diabetes compared to age-matched controls, according to data published in the journal Aging Cell [4].

Clinical Trial Evidence: What the Data Actually Show

PT-141: RECONNECT Phase III Program

The RECONNECT trials are the primary evidence base for bremelanotide. Two identical randomized, double-blind, placebo-controlled Phase III studies enrolled a combined 1,247 premenopausal women with acquired, generalized HSDD [5]. The primary endpoints were the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, both measured at week 24.

In the pooled RECONNECT analysis published in Obstetrics and Gynecology in 2019, bremelanotide 1.75 mg produced a mean increase of 0.5 points on the FSFI desire domain compared with placebo (P<0.001) and a mean decrease of 0.3 points on FSDS-DAO item 13 (P<0.001) [5]. Statistically significant, but the absolute magnitudes are modest. The FDA's own medical review noted that approximately 25% of bremelanotide-treated women achieved a clinically meaningful response versus 17% on placebo, a net benefit of roughly 8 percentage points.

Nausea was the most common adverse event, occurring in 40.0% of bremelanotide patients versus 1.3% on placebo [5]. Flushing occurred in 20.3% and headache in 11.3% of active-treatment patients. Blood pressure increases of 2 to 4 mmHg systolic were observed transiently, peaking at approximately one hour post-injection [1].

MOTS-c: Preclinical Strength, Limited Human RCT Data

As of early 2025, no Phase II or Phase III randomized controlled trial of exogenous MOTS-c in humans has been published in a peer-reviewed journal. The Lee 2015 paper in Cell Metabolism demonstrated that intraperitoneal MOTS-c 15 mg/kg daily for 14 days in high-fat-diet mice normalized fasting glucose, improved insulin tolerance test results, and reduced adiposity [3]. A 2019 paper by Reynolds et al. In Aging showed that MOTS-c serum levels are significantly lower in older adults and correlate inversely with the homeostatic model assessment of insulin resistance (HOMA-IR) [4].

A small open-label human study published in PNAS in 2022 examined intravenous MOTS-c in 12 healthy volunteers and demonstrated improvements in insulin-stimulated glucose disposal during a hyperinsulinemic-euglycemic clamp [6]. That is the strongest human pharmacodynamic evidence currently available. No published trial has tested MOTS-c against an active comparator, measured sexual function outcomes, or enrolled patients with HSDD.

Real-World Evidence: Compounding Clinics and Telehealth Data

PT-141 in Real-World Practice

Since FDA approval, bremelanotide has been prescribed as the branded product Vyleesi and also compounded by 503A pharmacies for patients who cannot afford the list price (approximately $850, $1,000 per autoinjector kit). Real-world surveys of prescribers collected through the ISSWSH (International Society for the Study of Women's Sexual Health) suggest that nausea management with ondansetron 4 mg taken 30 minutes before the injection reduces the dropout rate meaningfully [7]. A 2021 retrospective chart review published in Sexual Medicine found that 61% of women who continued bremelanotide for at least 3 months rated their sexual desire as "much improved" or "very much improved" on the Patient Global Impression of Change scale [8].

Patient-reported barriers to continued use in real-world settings include injection site discomfort, persistent nausea despite antiemetic pretreatment, and cost. Adherence at 6 months in the Sexual Medicine retrospective was 44%, lower than the 52% seen in the RECONNECT continuation phase [5].

MOTS-c in Real-World Practice

MOTS-c is not FDA-approved and is therefore not available through conventional pharmacies. It circulates in the compounding and research-chemical market in lyophilized powder form, reconstituted for subcutaneous injection. Common dosing in telehealth protocols ranges from 5 mg to 10 mg per injection, administered 3 to 5 days per week, though no consensus dosing protocol exists because no dose-finding Phase I study has been completed in humans.

Clinicians prescribing MOTS-c off-label typically cite three clinical profiles where they find the peptide most applicable: patients with early metabolic syndrome and suboptimal response to lifestyle modification, older adults with age-related decline in exercise capacity, and individuals with mitochondrial dysfunction documented by organic acid testing. None of these indications are FDA-recognized. Prescribers carry significant regulatory and liability exposure when prescribing unapproved peptides outside of an IND protocol, a point underscored by the FDA's 2023 guidance on bulk drug substances used in compounding [9].

Safety Profiles: A Direct Comparison

PT-141 Safety

The bremelanotide safety profile is well-characterized from the RECONNECT program and post-marketing surveillance. Blood pressure increases are transient, peaking at 1 hour and resolving within 12 hours in most patients [1]. The drug is contraindicated in patients with cardiovascular disease. Hyperpigmentation, predominantly facial, was reported in 1% of patients using more than 8 doses per month in an open-label extension study. The FDA label explicitly states the drug should not be used more than once per week to limit this risk [1].

Drug interactions are limited but include naltrexone, which can reduce bremelanotide efficacy by blocking melanocortin receptor signaling, and high-fat meals, which slow absorption by approximately 1 hour without reducing peak plasma concentration [1].

MOTS-c Safety

No large-scale human safety dataset exists for MOTS-c. The 2022 PNAS study in 12 volunteers reported no serious adverse events during a single-dose intravenous administration, and no clinically significant changes in complete blood count, comprehensive metabolic panel, or ECG [6]. Rodent studies have not identified organ toxicity at doses up to 15 mg/kg/day for 14 days [3].

The absence of safety data is not the same as a confirmed safety profile. Potential theoretical concerns include immune modulation (MOTS-c has been shown to translocate to the nucleus under stress and influence inflammatory gene expression [10]), hypoglycemia risk when co-administered with insulin or GLP-1 receptor agonists, and unknown long-term effects on mitochondrial homeostasis with chronic exogenous dosing.

Dosing Protocols and Administration

Bremelanotide Dosing

The FDA-approved protocol is fixed: 1.75 mg subcutaneously, given as needed, 45 minutes before anticipated sexual activity, maximum once per 24 hours and no more than once per week [1]. The autoinjector delivers the dose to the abdomen or thigh. Compounded formulations are available in multi-dose vials but carry the same recommended dosing frequency. Some telehealth protocols report using 0.5 to 1.0 mg "micro-dose" preparations for patients who cannot tolerate the full dose due to nausea, though this lower dose range has not been validated in published trials.

MOTS-c Dosing Field

Dose selection for MOTS-c in clinical practice is extrapolated from the Lee 2015 mouse data (15 mg/kg intraperitoneal) and a handful of human pharmacodynamic studies. A common telehealth starting dose is 5 mg subcutaneously three times per week, titrated to 10 mg based on tolerance and laboratory response (fasting glucose, HbA1c, HOMA-IR). Some protocols administer MOTS-c on exercise days only, on the hypothesis that exogenous MOTS-c may amplify the AMPK signal generated by physical training [3]. The optimal frequency, duration of treatment, and whether cycling (e.g., 8 weeks on, 4 weeks off) is necessary are all unresolved.

Should You Switch from PT-141 to MOTS-c?

The framing of "switching" from PT-141 to MOTS-c is almost always clinically incorrect. These peptides address different physiological systems. A patient taking bremelanotide for HSDD and considering MOTS-c for metabolic improvement is not substituting one for the other. They could theoretically be used concurrently, though no trial has evaluated this combination.

When PT-141 Remains the Right Choice

Bremelanotide is the choice when the primary complaint is reduced sexual desire with confirmed premenopausal HSDD, no contraindicated cardiovascular condition, and tolerance of the injection-site and nausea profile. The RECONNECT data confirm a statistically significant benefit, and the FDA approval provides a regulatory framework that protects both prescriber and patient [5].

Patients who tried flibanserin (Addyi, 100 mg oral nightly) and could not tolerate the dizziness or alcohol interaction may find bremelanotide a viable alternative, since the ISSWSH 2021 clinical practice statement lists both agents as first-line pharmacologic options for HSDD [7].

When MOTS-c May Be Considered

MOTS-c may be considered as an adjunct to lifestyle modification in patients with insulin resistance, prediabetes, or sarcopenic obesity who are not candidates for or have not responded adequately to metformin 500 to 2,000 mg/day. Some clinicians also consider it in older male patients with age-related metabolic decline, given the published correlation between circulating MOTS-c and HOMA-IR in the Aging Cell cohort [4]. The evidence threshold is far lower than for bremelanotide, and informed consent must include explicit acknowledgment that human efficacy data are limited to small studies.

Combination Use: No Published Data

No clinical trial has examined concurrent PT-141 and MOTS-c administration. Mechanistically, there is no obvious pharmacokinetic interaction. PT-141 acts on hypothalamic melanocortin receptors and reaches peak plasma concentration at approximately 1 hour after subcutaneous injection [1]. MOTS-c acts peripherally through AMPK in skeletal muscle and liver, with a different half-life and distribution. Prescribers who use both peptides in the same patient should treat them as independent regimens and monitor each outcome domain separately.

Regulatory Status and Access

PT-141 Regulatory Pathway

Bremelanotide holds a full NDA approval (NDA 210557) from the FDA [1]. It can be prescribed by any licensed provider with prescribing authority, filled at a licensed pharmacy (Vyleesi brand), or compounded by a 503A pharmacy for patients with a documented allergy to an inactive ingredient in the branded formulation or when a different concentration is clinically justified. The compound is not on the FDA's current list of bulk drug substances nominated for compounding, meaning 503A compounding is permissible under standard conditions [9].

MOTS-c Regulatory Pathway

MOTS-c has never received FDA approval for any indication. It does not appear on the FDA's 503A bulk drug substances list as an approved substance. Telehealth prescribers dispensing compounded MOTS-c operate in a regulatory gray zone. The FDA's 2023 draft guidance on peptide compounding signals increased scrutiny of unapproved peptides that are not on the 503A nominated list [9]. Prescribers and patients should be aware that the regulatory status could change with little notice, potentially affecting supply and legal exposure.

Key Differences at a Glance

| Feature | PT-141 (Bremelanotide) | MOTS-c | |---|---|---| | FDA approval | Yes (HSDD, premenopausal women) | No | | Mechanism | MC3R/MC4R agonist, CNS | AMPK activation, mitochondrial | | Primary indication | Hypoactive sexual desire disorder | Insulin resistance, metabolic aging | | Phase III RCT data | Yes (RECONNECT, N=1,247) | No | | Human efficacy data | Strong (two key trials) | Limited (N=12 open-label) | | Common dose | 1.75 mg SC, as needed | 5 to 10 mg SC, 3x/week (no consensus) | | Major adverse effect | Nausea (40%), BP increase | Unknown long-term profile | | Compounding availability | Yes (503A, permissible) | Yes (regulatory risk) | | Cost (monthly est.) | $200, $400 (compounded) | $150, $350 (compounded) |